Literature DB >> 16005406

Polypoidal choroidal vasculopathy: angiographic characterization of the network vascular elements and a new treatment paradigm.

Rogério A Costa1, Eduardo V Navajas, Michel E Farah, Daniela Calucci, Jose A Cardillo, Ingrid U Scott.   

Abstract

Macular exudative manifestations secondary to choroidal neovascular lesions remain the leading cause of definitive visual impairment and legal blindness in the elderly. During the past decade, advances in ophthalmic imaging systems have enabled the recognition of presumed new distinct choroidal neovascular lesions that share some unique clinical and angiographic peculiarities as well as better comprehension of the pathophysiologic mechanisms related to such entities. Amongst presumed newer exudative maculopathies, polypoidal choroidal vasculopathy, which has been described as a distinct choroidal abnormality characterized by inner choroidal vascular network of vessels ending in polyp-like structures only identified on indocyanine green angiography and mostly affecting African-American and Asian descendents, has gained special interest from the ophthalmic community particularly because of its growing recognition among patients with clinical appearance of neovascular age-related macular degeneration. Thus far, however, the exact nature of the vascular structure of the polypoidal choroidal vasculopathy lesion remains unclear and data from recent studies have conflicted with the initial concept of a benign exudative maculopathy with long-term preservation of good vision. All together, such factors make difficult the establishment of an appropriate treatment, if any, for the entity. Herein, by using a modified technique of conventional indocyanine green angiography, we demonstrate new information about the morphologic characteristics, and to some extent the blood flow dynamics perfusion, of the polypoidal choroidal vasculopathy lesion. Our results suggest that the PCV lesion should be considered a variety of choroidal neovascularization rather than a distinct clinical entity, characterized by one single large neovascular complex presenting well-defined arterial neovascular vessels arising from one major "ingrowth site" and draining vessels that present aneurysm-like dilations corresponding to the polyp-like structures typically described for the entity. Finally, the visual acuity and angiographic findings observed after selective ingrowth site photothrombosis corroborate the existence of one major "ingrowth site" for the PCV neovascular complex and point toward a new treatment paradigm for this variety of choroidal neovascularization.

Entities:  

Mesh:

Year:  2005        PMID: 16005406     DOI: 10.1016/j.preteyeres.2005.01.001

Source DB:  PubMed          Journal:  Prog Retin Eye Res        ISSN: 1350-9462            Impact factor:   21.198


  18 in total

1.  A comparison of risk factors for age-related macular degeneration and polypoidal choroidal vasculopathy in Chinese patients.

Authors:  Xiao-Li Chen; Qin-Rui Hu; Yu-Jing Bai; Yu Deng; Hai-Wei Wang; Shan Liu; Yin-Lin Wang; Yan-Kun Yue
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-06-01       Impact factor: 3.117

2.  Characteristics of fine vascular network pattern associated with recurrence of polypoidal choroidal vasculopathy.

Authors:  A Oishi; M Mandai; M Kimakura; A Nishida; Y Kurimoto
Journal:  Eye (Lond)       Date:  2011-05-06       Impact factor: 3.775

3.  Bevacizumab for serous changes originating from a persistent branching vascular network following photodynamic therapy for polypoidal choroidal vasculopathy.

Authors:  Kyu Seop Kim; Won Ki Lee
Journal:  Jpn J Ophthalmol       Date:  2011-06-07       Impact factor: 2.447

4.  En face imaging of the choroid in polypoidal choroidal vasculopathy using swept-source optical coherence tomography.

Authors:  Tarek Alasil; Daniela Ferrara; Mehreen Adhi; Erika Brewer; Martin F Kraus; Caroline R Baumal; Joachim Hornegger; James G Fujimoto; Andre J Witkin; Elias Reichel; Jay S Duker; Nadia K Waheed
Journal:  Am J Ophthalmol       Date:  2014-12-19       Impact factor: 5.258

5.  Time-lag between subretinal fluid and pigment epithelial detachment reduction after polypoidal choroidal vasculopathy treatment.

Authors:  Ju Byung Chae; Joo Yong Lee; Sung Jae Yang; June-Gone Kim; Young Hee Yoon
Journal:  Korean J Ophthalmol       Date:  2011-03-11

6.  Polypoidal choroidal vasculopathy appearing as classic choroidal neovascularisation on fluorescein angiography.

Authors:  Hiroshi Tamura; Akitaka Tsujikawa; Atsushi Otani; Norimoto Gotoh; Manabu Sasahara; Takanori Kameda; Daisuke Iwama; Yuko Yodoi; Michiko Mandai; Nagahisa Yoshimura
Journal:  Br J Ophthalmol       Date:  2007-02-21       Impact factor: 4.638

Review 7.  Verteporfin PDT for non-standard indications--a review of current literature.

Authors:  Wai Man Chan; Tock-Han Lim; Alfredo Pece; Rufino Silva; Nagahisa Yoshimura
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-02-17       Impact factor: 3.117

8.  Prevalence of focal lamina cribrosa defects in eyes with pachychoroid disease spectrum.

Authors:  Hae Min Kang; Na Eun Lee; Jeong Hoon Choi; Hyoung Jun Koh; Sung Chul Lee
Journal:  Int J Ophthalmol       Date:  2022-01-18       Impact factor: 1.779

9.  Combined photodynamic therapy and intravitreal bevacizumab for idiopathic polypoidal choroidal vasculopathy: one-year follow-up.

Authors:  Mario R Romano; Ugo Cipollone; Francesco Semeraro; Michele Rinaldi; Ciro Costagliola
Journal:  Clin Ophthalmol       Date:  2010-10-21

10.  Two-year follow-up of ranibizumab combined with photodynamic therapy for polypoidal choroidal vasculopathy.

Authors:  Rei Nemoto; Masahiro Miura; Takuya Iwasaki; Hiroshi Goto
Journal:  Clin Ophthalmol       Date:  2012-10-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.